Melanoma Research
Clinical activity centres on surgically resectable melanoma with high-risk features, including BRAF-mutated and BRAF wild-type disease. The sponsor’s studies focus on treatment strategies used around surgery and on disease control in stage III/IV (M0) settings.
- Neoadjuvant immunotherapy
- Adjuvant treatment
- High-risk resectable melanoma
- BRAF-mutated and wild-type disease
Research interests include immune-based approaches and combination strategies aimed at improving tumour response and reducing relapse risk in patients eligible for surgery.
Cutaneous Squamous Cell Carcinoma
The sponsor is also involved in high-risk cutaneous squamous cell carcinoma, particularly cases that remain surgically resectable. The clinical focus is on therapies used before and after surgery in locally advanced disease.
- High-risk cutaneous squamous cell carcinoma
- Surgical resectability
- Perioperative immunotherapy
This area reflects interest in immune checkpoint inhibition for controlling aggressive skin cancer and supporting durable disease management.
Immune-Oncology and Combination Therapy
Several funded trials explore immuno-oncology combinations in solid tumours with a focus on neoadjuvant and adjuvant use. The research landscape includes pairing checkpoint inhibitors with other immune-modulating agents and targeted therapies.
- Checkpoint blockade
- Combination immunotherapy
- Immune modulation
- Perioperative cancer treatment
These studies are directed toward strengthening anti-tumour activity in settings where surgery alone may not be sufficient to control recurrence.
